Immutep reports success with first in class immuno-agonist in metastatic breast cancer
Orsay - French Immutep S.A. has published results of a Phase I/II study demonstrating a combination of paclitaxel plus the firm's antigen-presenting cell (APC) agonist IMP321 achieved clinical benefit in 90% of metastatic breast carcinoma (MBC) patients (J Transl Med. 8:71) at 6 months. Patients of all three dose groups (doses: 0.25, 1.25 and 6.25 mg), which received 12 subcutanous injections of IMP321 every 2 weeks over 24 weeks plus paclitaxel, showed an sustained increase in the number and activation of monocytes and dendritic cells as well as a higher count of NK and long-lived cytotoxic effector-memory CD8 T cells. The firm announced its intention to carry out pivotal Phase III studies with the
recombinant soluble LAG-3Ig fusion protein that binds to MHC class II in different cancer indications.